Treatment with daily aspirin for 5 years or longer reduces subsequent risk of colorectal cancer. Several lines of evidence suggest that aspirin might also reduce risk of other cancers, particularly of the gastrointestinal tract, but proof in man is lacking.

We studied deaths due to cancer during and after randomised trials of daily aspirin versus control done originally for prevention of vascular events.